2020
Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19
Fu Y, Li Y, Guo E, He L, Liu J, Yang B, Li F, Wang Z, Li Y, Xiao R, Liu C, Huang Y, Wu X, Lu F, You L, Qin T, Wang C, Li K, Wu P, Ma D, Sun C, Chen G. Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19. Annals Of Internal Medicine 2020, 174: m20-3337. PMID: 33284684, PMCID: PMC7745119, DOI: 10.7326/m20-3337.Peer-Reviewed Original ResearchConceptsIndependent risk factorLaboratory-confirmed COVID-19Noncritically ill patientsViral positivityCritically ill patientsIll patientsDisease severityLow IgM titersRisk factorsViral polymerase chain reactionIgM titersCourse of coronavirus disease 2019Serum inflammatory markersIgM positive rateClinically diagnosed casesIgG positivity rateViral positivity rateMedian durationSpecialty care centersSeroconversion ratesAdult patientsInflammatory markersSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Polymerase chain reactionDevelopment and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia
Wu C, Luedtke A, Sadikova E, Tsai H, Liao S, Liu C, Gau S, VanderWeele T, Kessler R. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Network Open 2020, 3: e1921660. PMID: 32083693, PMCID: PMC7043195, DOI: 10.1001/jamanetworkopen.2019.21660.Peer-Reviewed Original ResearchConceptsFirst-episode schizophreniaAntipsychotic medicationPrescribed antipsychotic medicationTreatment success rateTreatment successSchizophrenic disordersFirst-episodeSuccess rateSchizophreniaProbability of treatment successTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseHealth Insurance Research DatabaseEstimating treatment successValidation sampleIndividualized treatment rulesMedicationPrognostic studyPatientsInvestigated biomarkersClinical implementationDischarge diagnosisClinical observationsDemographic dataPragmatic trialKras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesTime FactorsT-Lymphocytes, RegulatoryConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stage
2018
Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia
Huang J, Liu C, Hwang T, Chen Y, Hsu Y, Hwu H, Lin Y, Hsieh M, Liu C, Chien Y, Tseng W. Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia. Human Brain Mapping 2018, 39: 2007-2019. PMID: 29377322, PMCID: PMC6866389, DOI: 10.1002/hbm.23982.Peer-Reviewed Original ResearchConceptsGeneralized fractional anisotropyGeneralized fractional anisotropy valuesAdequate antipsychotic treatmentNegative symptom scoresNonremission groupWhite matter tract integrityWhite matter integrityHealthy controlsRemission stateWhite matter tract bundlesWhite matter tractsReduced integrationAntipsychotic treatmentNonremitted patientsSchizophrenia patientsSymptomatic remissionIllness durationAnalysis of covarianceSchizophreniaDiffusion spectrum imagingTract integrityPost hoc analysisFractional anisotropyMedication dosesEducation years
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2016
The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroupsWhich patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget 2016, 7: 29177-29186. PMID: 27081079, PMCID: PMC5045387, DOI: 10.18632/oncotarget.8690.Peer-Reviewed Original ResearchConceptsPancreatic head cancerResectable pancreatic head cancerLymph node ratioHead cancerLymph nodesTumor locationPara-aortic lymph node dissectionPara-aortic lymph node metastasisPara-aortic lymph nodesCurative surgical resectionLymph node dissectionIndependent prognostic factorLymph node metastasisPoor surgical outcomesDuctal adenocarcinoma patientsPoor prognostic markerPreoperative serum CA125Curative pancreaticoduodenectomyNode dissectionPancreatic headRadical surgerySurgical resectionNode metastasisPrognostic factorsSuch patientsImpact of universal health coverage on urban–rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan
Chiang C, Chen P, Huang L, Kuo P, Tung Y, Liu C, Chen W. Impact of universal health coverage on urban–rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan. BMJ Open 2016, 6: e010802. PMID: 26940114, PMCID: PMC4785302, DOI: 10.1136/bmjopen-2015-010802.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmbulatory CareDatabases, FactualFemaleHealthcare DisparitiesHumansKaplan-Meier EstimateLogistic ModelsMaleMental Health ServicesMiddle AgedNational Health ProgramsPatient AdmissionPsychotic DisordersRetrospective StudiesRural PopulationTaiwanUniversal Health InsuranceUrban PopulationYoung AdultConceptsUniversal health coverageService utilisationUrban-rural residenceUrban-rural inequalitiesHealth coverageUrban patientsEmergency departmentImplementation of universal health coverageImpacts of universal health coverageNationwide population-based studyQuality of careTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseRural-dwelling patientsHealth Insurance Research DatabasePopulation-based studyUrban-rural differencesPopulation coverage ratePsychiatric outpatient servicesMedical claims recordsNationwide cohort of patientsRisk of readmissionRural patientsUrban-rural gapPsychiatric readmission
2015
Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinoma
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survival18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, Hu S, Ni Q, Long J, Yu X. 18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. International Journal Of Oncology 2014, 45: 1531-1536. PMID: 25096059, DOI: 10.3892/ijo.2014.2570.Peer-Reviewed Original ResearchConceptsNon-functioning pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsPET/CTNeuroendocrine tumorsNon-functioning endocrine pancreatic tumorsPET/CT scansDistant metastatic lesionsShanghai Cancer CenterEndocrine pancreatic tumorsClinical characteristicsMetastatic lesionsTumor sizeCancer CenterTNM stagePancreatic tumorsLarge cohortCT scanClinical valueAdvanced stageSignificant associationTumorsPatientsCTCohortLesions
2012
CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survivalQuantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis
Jeung J, Patel R, Vila L, Wakefield D, Liu C. Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis. Archives Of Pathology & Laboratory Medicine 2012, 136: 610-7. PMID: 22646266, PMCID: PMC3806979, DOI: 10.5858/arpa.2011-0371-oa.Peer-Reviewed Original ResearchConceptsHER2/neu expressionHER2/neu overexpressionGE tumorsBreast cancerNeu expressionNeu overexpressionIHC expressionHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Anti-HER2/neu antibodyGE junction tumorsGrowth factor receptor 2IHC interpretationIHC scoring systemHER2/neuFactor receptor 2Conventional light microscopyGastroesophageal adenocarcinomaOverall survivalClinicopathologic featuresIHC 3Resection specimensIHC 2Tumor gradeBreast carcinoma
2011
Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience
Pan J, Oh S, Soldevila‐Pico C, Nelson D, Liu C. Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience. Clinical Transplantation 2011, 25: 164-170. PMID: 20156222, PMCID: PMC3480317, DOI: 10.1111/j.1399-0012.2010.01211.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCase-Control StudiesDNA, ViralFemaleFollow-Up StudiesGraft SurvivalHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoenzyme TechniquesLiver TransplantationMaleMiddle AgedPolymerase Chain ReactionPrevalenceRetrospective StudiesSurvival RateTissue DonorsTransplantation, HomologousTreatment OutcomeVirus ActivationConceptsHepatitis B virusDetectable HBV DNAHBV DNALiver allograftsLow prevalenceDe novo hepatitis B.Serum HBV DNA levelsHepatitis B core antigenHepatitis B surface antigenHBV DNA levelsSingle-center experienceB core antigenLiver biopsy tissueB surface antigenViral protein expressionHBV serologySeronegative recipientsHBV infectionHepatitis B.Such prophylaxisPositive donorsCore antigenRetrospective studyB virusProphylaxis
2009
Loss of Carbamoyl Phosphate Synthetase I in Small-Intestinal Adenocarcinoma
Cardona D, Zhang X, Liu C. Loss of Carbamoyl Phosphate Synthetase I in Small-Intestinal Adenocarcinoma. American Journal Of Clinical Pathology 2009, 132: 877-882. PMID: 19926579, DOI: 10.1309/ajcp74xgrfwtflju.Peer-Reviewed Original ResearchConceptsCases of duodenitisWestern blot analysisHep Par 1 antibodyHep Par 1 expressionHep Par 1Low-grade dysplasiaPAR-1 expressionBlot analysisExpression of CPS1CPS1 expressionIntestinal adenocarcinomaImmunohistochemical findingsInvasive adenocarcinomaInvasive tumorsMalignant tumorsAntigen expressionNormal mucosaControl groupAdenocarcinomaPAR-1AdenomasSmall intestine enterocytes
2006
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum
Winfield R, Hochwald S, Vogel S, Hemming A, Liu C, Cance W, Grobmyer S. Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum. The American Surgeon 2006, 72: 719-723. PMID: 16913316, DOI: 10.1177/000313480607200811.Peer-Reviewed Original ResearchConceptsDuodenal gastrointestinal stromal tumorGastrointestinal stromal tumorsSmall bowel gastrointestinal stromal tumorsGastric gastrointestinal stromal tumorsStromal tumorsPartial duodenal resectionHistory of neurofibromatosisPortion of duodenumDuodenal resectionGastrointestinal bleedingMedian sizeAdjuvant therapyCommon presentationComplete resectionRetrospective reviewSmall bowelRare tumorCase reportSingle institutionIncidental findingPatientsPancreaticoduodenectomyResectionTumorsDuodenum
2005
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system